Participant flow

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) · Source last updated 2026-05-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity

   id

   FG000

   title

   Treatment (Copanlisib)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         18

      type

      Disease progression

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Other complicating disease

   4. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Withdrawal by Subject

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Physician Decision

   6. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Still on treatment

   7. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Never start protocol therapy

   8. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Ineligible

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         35

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         31

      type

      Eligible

   3. achievements

      1. group Id

         FG000

         num Subjects

         30

      type

      Started Protocol Therapy

   4. achievements

      1. group Id

         FG000

         num Subjects

         28

      type

      Eligible and Treated

   5. achievements

      1. group Id

         FG000

         num Subjects

         30

      type

      Mutation Status Confirmed

   6. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      Eligible, Treated and Mutation Status Confirmed

   7. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   8. achievements

      1. group Id

         FG000

         num Subjects

         35

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The PIK3CA mutations status was determined by a CLIA-approved assay performed in a NCI-MATCH approved laboratory for all patients in this arm. Mutation status was confirmed for 30 patients based on confirmation report as of August 1, 2019.

recruitment Details

Subprotocol Z1F was activated on June 20, 2018. Thirty-five patients were enrolled between June 2018 and December 2018.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice